An oral SARS-CoV-2 M <sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19
2021 · Science · 1,855 citations
https://doi.org/10.1126/science.abl4784
B
Britton Boras
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
40
Papers
3.1K
Citations
16
h-index
18
i10-index
Britton Boras is an academic researcher from Pfizer (United States). The author has contributed to research in topics: Advanced Breast Cancer Therapies & Cancer-related Molecular Pathways & SARS-CoV-2 and COVID-19 Research. The author has an h-index of 16, co-authored 34 publications.
ORCID: 0000-0003-3624-9177Papers by this author
worksPreclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19
2021 · Nature Communications · 288 citations
https://doi.org/10.1038/s41467-021-26239-2
Nanoparticles for Improved Local Retention after Intra-Articular Injection into the Knee Joint
2012 · Pharmaceutical Research · 81 citations
https://doi.org/10.1007/s11095-012-0870-x
CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety
2025 · Cancer Cell · 35 citations
https://doi.org/10.1016/j.ccell.2025.02.006
Current practices for QSP model assessment: an IQ consortium survey
2022 · Journal of Pharmacokinetics and Pharmacodynamics · 23 citations
https://doi.org/10.1007/s10928-022-09811-1
Quantitative systems toxicology modeling in pharmaceutical research and development: An industry‐wide survey and selected case study examples
2024 · CPT Pharmacometrics & Systems Pharmacology · 10 citations
https://doi.org/10.1002/psp4.13227
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat